Valuation: Grace Therapeutics, Inc.

Market Cap 51.77M 36.5M 31.89M 29.28M 27.31M 3.47B 52.65M 353M 137M 1.7B 137M 134M 5.87B P/E 2027 *
-4.32x
P/E 2028 * -4.11x
Enterprise Value 51.77M 36.5M 31.89M 29.28M 27.31M 3.47B 52.65M 353M 137M 1.7B 137M 134M 5.87B EV / Sales 2027 *
-
EV / Sales 2028 * 6.61x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day+5.36%
1 week-0.63%
Current month+3.74%
1 month-5.80%
3 months-54.09%
6 months-35.66%
Current year-31.94%
1 week 2.08
Extreme 2.0782
2.45
1 month 2.08
Extreme 2.0782
2.57
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.74
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 04/04/2023
Director of Finance/CFO 54 05/01/2024
Chief Tech/Sci/R&D Officer 64 08/05/2023
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 04/04/2023
Director/Board Member 59 10/10/2023
Date Insider Type Main position Quantity % Market Cap.
01-12Option

Director

10,000 0.0646%
01-12Option

Director

10,000 0.0646%
01-12Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+5.36%-0.63%-22.02%-24.81% 36.45M
+3.98%+5.55%+76.40%+136.18% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.69%+8.31%-9.96%-9.59% 23.75B
+2.99%+4.64%+11.28%+426.84% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+1.89%+3.15%+23.94%+187.01% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +3.20%+6.14%+46.05%+126.01% 23.59B
Weighted average by Cap. +2.10%+6.09%+57.31%+135.45%

Financials

2027 *2028 *
Net sales - 7.83M 5.52M 4.83M 4.43M 4.13M 526M 7.97M 53.35M 20.68M 258M 20.73M 20.28M 888M
Net income -12.76M -8.99M -7.86M -7.22M -6.73M -856M -12.97M -86.89M -33.68M -420M -33.77M -33.04M -1.45B -20.46M -14.43M -12.61M -11.58M -10.79M -1.37B -20.81M -139M -54.01M -674M -54.17M -52.99M -2.32B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
02/07/26 $2.355 +5.13% 246,943
01/07/26 $2.240 -1.32% 251,044
30/06/26 $2.270 -1.30% 409,178
29/06/26 $2.300 -3.36% 994,744
26/06/26 $2.380 +0.42% 269,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.181CAD
Average target price
8.447CAD
Spread / Average Target
+165.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock